Once-Daily Orforglipron Tablet Outperformed Placebo for Weight Loss

CATEGORY: DIET & WEIGHT

Adults with obesity who took the once-daily pill orforglipron for 72 weeks lost an average of 11.2% of their body weight at the highest dose, compared with 2.1% among those taking a placebo, in a randomized trial of 3,127 adults published in the New England Journal of Medicine.¹ The medication, sold as Foundayo, was approved by the U.S. Food and Drug Administration in April 2026 as the first weight-loss drug of its kind that comes as a tablet with no food or water restrictions.

A Small Molecule Pill Instead of Weekly Injections

Orforglipron belongs to the GLP-1 receptor agonist family—drugs that mimic a gut hormone which tells your brain you are full and slows how quickly your stomach empties. Until now the most effective members of this family, semaglutide and tirzepatide, have been weekly injections, and the one earlier tablet version had to be taken on an empty stomach with a long wait before eating. Orforglipron is a small molecule rather than a copy of the hormone itself, which is what allows it to be swallowed at any time of day.¹

ATTAIN-1 Tested 6, 12 and 36 Milligram Doses

The trial, called ATTAIN-1, enrolled adults with obesity but without diabetes at sites in several countries. Participants were randomly assigned to one of three daily doses—6, 12 or 36 milligrams—or to an identical-looking placebo, and neither they nor their doctors knew which they received. Everyone was also given advice on healthy eating and physical activity. Body weight was measured in clinic over 72 weeks, and the main result counted every participant who was randomized, whether or not they stayed on the tablets—a more realistic picture of ordinary use.¹ Percent change in body weight at week 72 was the trial’s prespecified main endpoint, and every dose showed significantly greater loss than placebo.¹

54.6% Lost at Least a Tenth of Body Weight

Average weight loss was 7.5% at the lowest dose, 8.4% at the middle dose and 11.2% at the highest, versus 2.1% with placebo. Among people on the highest dose, 54.6% lost at least a tenth of their body weight, 36.0% lost at least 15% and 18.4% lost at least a fifth, compared with 12.9%, 5.9% and 2.8% of the placebo group. Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol also improved more with the drug.¹

Digestive Side Effects and Eli Lilly Funding

The most common side effects were digestive—nausea, constipation and similar complaints—and were mostly mild to moderate. Between 5.3% and 10.3% of people on orforglipron stopped because of side effects, compared with 2.7% on placebo. The trial was funded by Eli Lilly, the drug’s maker, and it lasted 72 weeks, so what happens over many years, or after stopping the tablets, was not tested here. The trial also excluded people with diabetes, and it did not compare the pill head-to-head with the injectable drugs.¹

Nine Trials, 5,766 Adults, Low to Moderate Certainty

Other trials of oral GLP-1 drugs point the same way. A 2026 pooled analysis of nine randomized trials covering 5,766 adults with overweight or obesity and no diabetes found that every drug tested except one low-dose option beat a dummy pill on weight loss, and that orforglipron and the highest dose of oral semaglutide showed the largest effects. The researchers rated the certainty of that evidence as low to moderate.²

Key Takeaways

• In 3,127 adults with obesity, a once-daily orforglipron tablet at its highest dose was linked to 11.2% average weight loss over 72 weeks, versus 2.1% with placebo.
• Roughly one in three people on the highest dose lost 15% or more of their body weight, compared with about one in seventeen on placebo.
• Digestive side effects were common but mostly mild to moderate; about one in ten on the top dose stopped because of them.
• The drug was approved in the U.S. in April 2026; longer-term effects and direct comparisons with injectable GLP-1 drugs were not part of this trial.

References

1. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796–1806. link
2. Kamrul-Hasan ABM, Ashraf H, Nagendra L, et al. Role of oral glucagon-like peptide-1 receptor agonists in weight management for individuals with overweight or obesity without diabetes: a network meta-analysis of randomized controlled trials. Obesity Science & Practice. 2026;12(4):e70181. link.